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ABSTRACT 
Background 
Despite remarkable results with salvage standard-dose or high-dose chemotherapy 
about 15% of patients with relapsed germ-cell tumors (GCT) are incurable. Immune 
checkpoint inhibitors have produced significant remission in multiple tumor types. We 
report the first study of immunotherapy in patients with GCT.  
Patients and Methods  
Single arm phase 2 trial investigating pembrolizumab 200mg IV Q3weeks until disease 
progression in patients with relapsed GCT and no curable options. Patients age≥18 with 
GCT who progressed after first-line cisplatin-based chemotherapy and after at-least 1 
salvage regimen (high-dose or standard-dose chemotherapy) were eligible. Centrally 
assessed programmed death-ligand 1 (PD-L1) on tumor and infiltrating immune cells 
was scored. Primary endpoint was overall response rate (ORR) using immune-related 
response criteria. Simon two-stage design with type I error 20% and power 80% was 
utilized.  
Results 
12 male patients were enrolled. Median age 38. All patients had non-seminoma. 
Primary site was testis (11) or mediastinum (1). Median AFP 615 (range,1-32,760) and 
hCG 4 (range,0.6-37,096). 6 patients had late relapse (>2years). Median number of 
previous chemotherapy regimens was 3. 6 patients received prior high-dose 
chemotherapy. 2 patients had positive PD-L1 staining (H-score 90 and 170). Median 
number of pembrolizumab doses was 2 (range,1-8). There were 6 grade 3 adverse 
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events. No immune-related adverse events were reported. No partial or complete 
responses were observed. 2 patients achieved radiographic stable disease for 28 and 
19 weeks, respectively; both had continued rising AFP level despite radiographic 
stability and had negative PD-L1 staining. 
Conclusion 
This is the first reported trial evaluating immune checkpoint inhibitors in GCT. 
Pembrolizumab is well tolerated but does not appear to have clinically meaningful 
single-agent activity in refractory GCT. 
Clinical trial information:NCT02499952. 
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Key Message 
In this phase II trial, pembrolizumab was well tolerated but did not appear to have single 
agent activity in refractory germ cell tumors. Two patients had stable disease while the 
rest had progressive disease as best response. Programmed death-ligand 1 (PD-L1) 
staining was positive in 2 patients.  
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INTRODUCTION 
Germ-cell tumors (GCT) are remarkably chemosensitive and up to 80% of patients with 
metastatic disease will be cured with cisplatin-based combination chemotherapy.[1] 
Patients who relapse after initial chemotherapy can still be cured with salvage therapy 
including salvage surgery, standard dose chemotherapy, or high-dose chemotherapy 
plus peripheral-blood stem cell transplant (PBSCT).[2-7] Despite the high cure rates 
with frontline and salvage chemotherapy, there remains a 15-20% cohort of patients 
with metastatic GCT who are incurable with the current therapeutic options. Novel 
therapeutic approaches are needed for these patients.  
Monoclonal antibodies against programmed death 1 (PD-1) and its ligands (PD-L1 and 
PD-L2) have demonstrated robust activity and manageable toxicity in many advanced 
tumors including melanoma, lung, kidney, urothelial, and other malignancies.[8-11] 
Pembrolizumab is a highly selective, humanized monoclonal IgG4κ isotype antibody 
against PD-1 which can disrupt the engagement of PD-1 with its ligands and impede 
inhibitory signals in T cells.  
Frequent PD-L1 expression has been reported in tumor samples from testicular cancer 
patients suggesting that these patients could potentially benefit from immunotherapy 
approaches with PD-1 or PD-L1 inhibition.[12] In addition, a prognostic value has been 
suggested for PD-L1 expression on testicular GCT indicating that patients with high PD-
L1 expression were more likely to have poor clinical features and worse survival 
outcomes.[13] Case series have been reported regarding possible activity of PD-1 
inhibitors in combination with chemotherapy in a small sample of 4 patients with 
platinum refractory GCT.[14]  
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Immune therapy with Pembrolizumab is a novel approach for salvage in patients with 
metastatic GCT. In a multicenter single-arm open-label phase II trial conducted within 
the Hoosier Cancer Research Network, we evaluated the efficacy and safety of 
pembrolizumab in patients with refractory GCT with no further curative treatment 
options.  
PATIENTS AND METHODS 
Patients 
Eligible patients had histologically confirmed metastatic GCT (seminoma or non-
seminoma histology) who progressed after first-line cisplatin-based chemotherapy and 
after at-least one salvage regimen: standard-dose chemotherapy or high-dose 
chemotherapy plus peripheral-blood stem-cell transplant. Relapsed patients who are not 
eligible for salvage chemotherapy (e.g. late relapse of disease) were also included in 
this study. An Eastern Cooperative Oncology Group (ECOG) performance status score 
of 0 or 1 was required (on a 5-point scale, with 0 indicating no symptoms and higher 
numbers indicating greater disability). Patients had measurable metastatic disease 
according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 
and/or elevation of tumors markers (alpha-fetoprotein [AFP] and/or β-human chorionic 
gonadotropin [β-hCG]).[15] If a rising tumor marker was the only evidence of 
progressive disease, 2 consecutive rising values at least one week apart were required. 
Patients with treated brain metastases were eligible. Treatment with systemic 
corticosteroids or immunosuppressants within 7 days of first trial treatment was not 
permitted.  All patients were required to provide archived tumor tissue from a biopsy or 
the original primary tumor for PD-L1 expression evaluation and other exploratory 
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analyses. Patients were eligible irrespective of PD-L1 staining result. Patients were 
ineligible if they had received anti-PD-1 or anti-PD-L1 therapy previously. Full eligibility 
criteria are listed in the trial protocol, available online with the full text of this article.  
Pretreatment Evaluation 
Pretreatment evaluation included complete history and physical examination, 
performance status, complete blood count, comprehensive metabolic profile, serum 
tumor markers (AFP and hCG), creatinine clearance, electrocardiogram, and computed 
tomography (CT) scan of the chest, abdomen, and pelvis. 
Treatment Program 
Planned treatment consisted of pembrolizumab 200mg administered intravenously (IV) 
every 3 weeks. Pembrolizumab was provided by Merck & Co., the supporter of this 
investigator initiated phase II trial. Treatment was continued until documented disease 
progression, development of unacceptable level of toxic effects, withdrawal of consent, 
decision by investigator to discontinue treatment, or the completion of 52 weeks of 
pembrolizumab therapy.  
Evaluation of Response and Toxicity 
Patients were assessed on day 1 of each 3-week cycle. A complete blood count, 
complete metabolic panel, and tumor markers were determined on day 1 of each cycle. 
Toxicities were graded according to the National Cancer Institute Common Terminology 
Criteria for Adverse Events, version 4.0. Tumor imaging was performed at baseline 
followed by every 6 weeks for the initial 18 weeks. Subsequently, imaging was spaced 
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to every 12 weeks until discontinuation of study drug. The full assessment schedule is 
provided in the trial protocol. 
PD-L1 expression was assessed in formalin-fixed archived tumor samples at a central 
laboratory with the use of the commercially available PD-L1 IHC 22C3 assay. PD-L1 
expression was scored as 0 (no staining), 1 (weak staining), 2 (moderate staining), 3 
(intense staining) along with categorized PD-L1 combined positive score, defined as the 
percentage of PD-L1-expressing tumor and infiltrating immune cells relative to the total 
number of tumor cells (H-score).  
Endpoints and Statistical Analysis  
The primary endpoint was overall response rate (ORR) using immune related response 
criteria (irRC).[16] Secondary endpoints were ORR using RECIST version 1.1, to 
assess toxicity and tolerability of pembrolizumab, and to estimate the duration of 
disease response.[15] Exploratory objectives included assessment of prevalence of PD-
L1 expression in tumor tissue and correlate with tumor response to treatment. Efficacy 
was assessed in the intention-to-treat population, which included all the patients who 
were assigned to the treatment group. Safety was assessed in the as-treated 
population, which included all the patients who received at least one dose of study 
treatment. 
A Simon two-stage optimal design with type I error rate of 20% and power of 80% was 
utilized.[17] The null hypothesis was an ORR of ≤ 10% and the alternate hypothesis 
was ORR ≥ 15%. Consequently, 12 subjects were enrolled in the first stage. If no 
responses are determined in the initial stage, the study will be concluded.  If at least 1 
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patient achieved a partial or complete response, then the treatment will be considered 
worthy of further investigation and 8 more subjects will be accrued in the second stage 
for a total sample size of 20 subjects. If there are 3 or more subjects with partial or 
complete response, then the treatment regimen would be considered a success. 
Statistical analyses were performed using SAS software, version 9.4. The data cutoff 
was February 2017. The study schema is depicted in figure 1.  
RESULTS 
Patient and Disease Characteristics 
Twelve patients were enrolled between March and October 2016. Patient characteristics 
are provided in Table 1. Median age was 38 years (range, 27 to 55 years) and all 
patients were male. Primary tumor sites was testis in 11 patients (92%) and mediastinal 
non-seminoma in 1 patient (8%). All patients had non-seminoma histology. Tumor 
markers were elevated in all patients: AFP only in 3, hCG only in 3, both AFP and hCG 
were elevated in 6 patients. Metastatic sites included retroperitoneal lymph nodes in 5 
patients, pulmonary metastasis in 9 patients, liver metastasis in 3 patients, brain and 
bone metastasis in 1 patient each. The median number of previous chemotherapy lines 
of treatment was 3 (range, 1 to 6). Six patients (50%) received prior high-dose 
chemotherapy and autologous stem-cell transplant as a previous line of therapy. Ten 
patients had received prior ifosfamide or paclitaxel-containing salvage chemotherapy 
regimens. Six patients (50%) had late relapse of disease defined as disease that 
relapsed more than 2 years after first-line cisplatin-based combination chemotherapy.  
Treatment Administration  
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All 12 patients enrolled received at least one dose of pembrolizumab 200mg IV per 
study protocol. The median number of pembrolizumab doses was 2 (range, 1-8). Two 
patients received only 1 dose of pembrolizumab and had clear clinical disease 
progression at the time of the scheduled second dose. Eight patients received 2 doses 
of pembrolizumab and had disease progression at the 6 week interim evaluation. One 
patient received 6 doses and another patient received 8 doses of pembrolizumab.  
Efficacy 
No partial or complete responses were observed. Two patients achieved stable disease 
for 28 and 19 weeks, respectively. Both these patients had continued rising AFP values 
on treatment despite radiographic stability. One of these patients had late relapse with 
no response to previous salvage standard-dose chemotherapy (paclitaxel-ifosfamide-
cisplatin [TIP] and paclitaxel-gemcitabine) before enrolling on this clinical trial. The 
second patient with radiographic stability did not have late relapse of disease and had 
slow progression after salvage standard-dose chemotherapy with TIP and gemcitabine-
oxaliplatin. Ten patients had progressive disease as their best response. None of the 
patients on study had tumor marker decline while on treatment with pembrolizumab.  
Per study protocol, at least 1 objective response was required to continue enrolling on 
the second stage of the study; therefore, the trial was closed at the completion of the 
first stage. At last follow-up, 6 of the 12 patients enrolled had died of disease 
progression.  
Biomarker Analysis 
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Archival formalin-fixed paraffin-embedded tissue samples were available for correlative 
studies in all patients. Correlative studies were performed on samples from primary 
testicular tumor in 4 patients, retroperitoneal lymph nodes in 6 patients, bone metastasis 
biopsy sample in 1 patient, and lung metastasis biopsy sample in 1 patient. 
Immunohistochemistry staining of archival tumor samples was positive for PD-L1 
expression in 2 patients: one patient with predominant embryonal carcinoma histology 
had 3+ staining in 30% of tumor cells formulating an H-score of 90. Another patient with 
predominant choriocarcinoma histology had 1+ staining on 50%, 2+ staining on 30%, 
and 3+ staining on 20% of tumor cells formulating an H-score of 170. Both these 
patients had progressive disease as their best response to therapy.  
Toxicity 
Pembrolizumab was tolerated by this patient population with 6 patients experiencing 
grade 3 adverse events. Four adverse events were possibly related to disease or study 
treatment. Grade 3 or higher and most commonly occurring adverse events are listed in 
Table 2. No grade 4 or 5 toxicities were observed. There were no immune-related 
adverse events observed.  
DISCUSSION 
In the current era, cisplatin-based combination chemotherapy will cure > 80% of 
patients with metastatic GCT.[18] 90% of patients with International Germ-Cell Cancer 
Collaborative Group (IGCCCG) good-risk disease will achieve cure with front-line 
chemotherapy. Patients with intermediate and poor-risk disease have less favorable 
outcomes and a significant proportion will relapse and require salvage therapy.[19] 
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High-dose chemotherapy plus PBSCT achieves cures in 60% of patients with relapsed 
metastatic GCT.[2, 3, 20] Patients who relapse after salvage standard-dose or high-
dose chemotherapy have poor outcomes with no further curative options short of 
salvage surgery in patients with anatomically localized disease.[7, 21]  
Understanding the mechanism(s) of resistance to treatment are desperately needed. 
Unfortunately, early studies with molecularly targeted therapies such as imatinib, 
sunitinib, thalidomide, and trastuzumab have yielded negative results.[22-25] More 
recently, studies with pazopanib have provided some signal of activity.[26] 
Immunotherapy with PD-1 and PD-L1 inhibitors has demonstrated remarkable results in 
a variety of advanced solid malignancies after progression on standard-of-care 
treatment.[8-11] Preclinical investigations have shown that PD-L1 expression was 
present in 73% of all seminomas and 64% of non-seminomas.[12] Our study represents 
the first clinical trial investigating immunotherapy with checkpoint inhibitors as a novel 
approach in patients with platinum-refractory incurable GCT.   
Pembrolizumab was tolerated in this study with no immune-related adverse events 
reported. Unfortunately, this clinical trial did not show clinical activity for pembrolizumab 
in patients with metastatic GCT who progressed after salvage chemotherapy. No 
objective responses were observed among the 12 patients enrolled; although 2 patients 
had radiographic stable disease for 28 and 19 weeks respectively, both had continued 
rising AFP level during treatment suggesting continued treatment resistance. PD-L1 
expression was present on tumor samples from only 2 patients in this study. Both these 
patients had progressive disease as their best response.  
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Although this phase II trial investigated a novel approach for salvage in refractory GCT, 
there are limitations to report. The small cohort of patients limits the generalizability. 
Other studies are underway investigating single agent or combination checkpoint 
inhibition in patients with metastatic GCT. Immunohistochemistry staining for PD-L1 was 
performed on archival tumor tissues which may not represent the current immune status 
or the tumor microenvironment at the time of treatment with checkpoint inhibitor. In 
addition, PD-L1 expression from tumor metastatic sites was not performed and this 
might also be informative. The expression of PD-L1 is known to be dynamic and is 
regulated by extrinsic signaling such as release of interferon-γ by immune cells, loss of 
expression of tumor suppressor genes, or activation of the AKT-mTOR pathway.[27, 28] 
Moreover, this study was not a biomarker driven study since all patients were eligible 
irrespective of PD-L1 expression. Higher levels of PD-L1 expression have been 
associated with robust responses in certain advanced solid tumors such as melanoma 
and lung cancer but not in others.[10, 11] In addition, the protocol for this study 
mandated response assessment at 6 weeks, i.e. after 2 infusions of pembrolizumab at 
which time most patients had progressive disease. This might have been a short 
interval given our understanding that the immune checkpoint inhibitors have a median 
time to response of ≥ 2months.[8, 10] Nevertheless, patients on this study had clinical 
unequivocal rapid progression while on study treatment. Even though no immune-
related adverse events were observed, the short duration of exposure to 
pembrolizumab with a median number of deliverable doses of 2 might influence that 
analysis.  
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In conclusion, this is the first reported clinical trial evaluating immune checkpoint 
inhibitors in testicular cancer. Single agent pembrolizumab did not demonstrate clinical 
benefit in this cohort of patients with refractory GCT. Further investigation requires 
evaluation of the mechanism of resistance and possible combination therapy.  
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FIGURE LEGENDS 
- Fig 1: Study schema  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Patient and Disease Characteristics  
Characteristic  No. of Patients % 
Total patients 12  
Median age (range) 38 (27-55)  
Location of primary tumor 
• Testis 
• Retroperitoneum 
• Mediastinum 
 
11 
0 
1 
 
92% 
0% 
8% 
Tumor histology 
• Seminoma 
• Non-seminoma 
 
0 
12 
 
0% 
100% 
Predominant histology 
• Choriocarcinoma 
• Embryonal carcinoma 
• Teratoma 
• Yolk Sac Tumor 
 
3 
5 
1 
3 
 
25% 
42% 
8% 
25% 
Metastatic site(s) 
• Retroperitoneum 
• Pulmonary 
• NPVM 
-Liver metastasis 
-Brain metastasis* 
-Bone metastasis* 
 
5 
9 
5 
3 
1 
1 
 
42% 
75% 
42% 
25% 
8% 
8% 
No. of previous chemotherapy regimens 
• 1 
• 2 
• 3 
• 4 
• 5 
• 6 
 
1 
0 
7 
2 
1 
1 
 
8% 
0% 
58% 
17% 
8% 
8% 
Late Relapse (> 2 years) 6 50% 
Elevated Tumor Markers 
• AFP only 
• hCG only 
• AFP and hCG 
 
3 
3 
6 
 
25% 
25% 
50% 
Median Serum AFP ng/mL (range) 615 (1-32,760)  
Median Serum hCG mIu/mL (range) 4 (0.6-37,096)  
ECOG performance status 
• 0 
• 1 
 
5 
7 
 
42% 
58% 
Abbreviations: NPVM, non-pulmonary visceral metastasis; AFP, alpha fetoprotein; HCG, 
human chorionic gonadotropin; IU, international unit; ECOG, Eastern Cooperative Oncology 
Group;  
*Brain/bone imaging was not mandatory  
 
Table 2. Common and Grade 3 or Higher Adverse Events Observed with Pembrolizumab 
Therapy 
 
 
Adverse Event Grade 1 Grade 2 Grade 3 Percent 
Fatigue 4 2 0 50% 
Nausea 4 1 0 42% 
Vomiting 4 0 0 33% 
Abdominal pain 2 0 1 25% 
Diarrhea 3 0 0 25% 
Skin and 
subcutaneous 
tissue disorders 
2 0 1* 25% 
Constipation 1 1 0 17% 
Cough 2 0 0 17% 
Dry skin 2 0 0 17% 
Dyspnea 1 1 0 17% 
Edema limbs 2 0 0 17% 
Flank pain 0 2 0 17% 
Flu-like 
symptoms 2 0 0 17% 
Musculoskeletal 
and connective 
tissue disorder 
1 1 0 17% 
Non-cardiac 
chest pain 0 1 1 17% 
Anemia 0 0 1 8% 
Hyperglycemia 0 0 1 8% 
Sciatic pain 0 0 1 8% 
*Erythema at patch site 
Fig 1.  
 
 
 
 
 
